News Archive

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between parti

A study by the Duke Clinical Research Institute comparing three treatment methods of preventing malaria in children with sickle cell anemia (SCA) found one method reduces common complications of the disease. EPiTOMISE: Enhancing Preventive Therapy Of Malaria in Children with Sickle cell anemia in East Africa, was conducted among children with SCA in Homa Bay, Kenya, where malaria is common. It evaluated the effects of a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) or a monthly combination of dihydroartemisinin-piperaquine (DP) against the standard of care in Kenya, Proguanil.

A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.

Less complex heart patients may benefit, but not without risk

In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths,

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the

New research shows COVID-19 patients have a higher likelihood of heart failure post-discharge

Pulmonary rehabilitation is an important evidenced-based treatment to improve health and quality of life for people living with Chronic Obstructive Pulmonary Disease (COPD). Now, new research from the Duke Clinical Research Institute has shown that the benefits of pulmonary rehabilitation are likely to extend beyond the patient to reduce costs for the health care system as well – with an estimated savings of more than $5,000 per patient.

If you want to change patient and provider behavior to improve a patient’s health, will an informational mailer make a difference?

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health with support from the Duke Clinical Research Institute shows that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – substantially improved clinical status and reduced deaths.